Bayer和NextRNA签署547M号合作协议, Bayer and NextRNA sign $547M collaboration to develop oncology therapies targeting lncRNAs.

Bayer和NextRNA治疗公司签署了一项547M美元的战略合作计划,以开发针对肿瘤学方面长期无编码的RNAs(NcRNAs)的小分子。 Bayer and NextRNA Therapeutics signed a $547M strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology. NextRNA 将获得前期和近期里程碑付款、研究资金、开发和商业里程碑付款，以及净销售额的分级特许权使用费。 NextRNA will receive upfront and near-term milestone payments, research funding, and development and commercial milestone payments, plus tiered royalties on net sales. 这项合作旨在通过抑制 lncRNA 功能, 推进瘤学新型小分子疗法. The partnership aims to advance novel small molecule therapeutics in oncology by inhibiting lncRNA function.